Exploring Serotonergic Psychedelics as a Treatment for Personality Disorders

Neuropharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 110413 - 110413

Published: March 1, 2025

Language: Английский

---

Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach

Frontiers in Psychiatry, Journal Year: 2025, Volume and Issue: 16

Published: April 2, 2025

Pathological narcissism (PN) is a complex, treatment-resistant disorder characterized by unstable self-esteem that fluctuates between grandiosity and vulnerability, complicating the formation of stable self-image. With few empirically supported therapies, treatment has traditionally relied on long-term psychoanalytic approaches, but these often face high attrition. Recent research suggests potential therapeutic synergy psychedelics therapy, offering novel approach to addressing entrenched personality structures. Studies MDMA (3,4-methylenedioxymethamphetamine), compound known for enhancing empathy, trust, social interactions, demonstrate reopen critical periods learning in adults, possibility benefits conditions with core issues relatedness, such as PN. promotes psychological flexibility openness, allowing deeper self-exploration strengthening observing ego, considered therapy be an essential component recognizing modifying maladaptive patterns. By reducing fear-based avoidance brain, facilitates access unconscious emotions, helping individuals process overwhelming feelings linked early relational trauma commonly seen Additionally, MDMA’s capacity enhance compassion empathy can fortify alliance, increasing its facilitate change. This paper presents MDMA-assisted (MDMA-AT) tailored narcissistic patients which currently being conducted investigator-initiated trial (IIT). It explores model’s theoretical foundations, mechanisms change, framework, clinical challenges. Combining evidence-based depth like psychotherapy may offer innovative associated attachment developmental trauma, particularly disorders. While role psychedelic treatments remains topic debate, some proposing administered without psychotherapy, we assert stand most gain from integrated psychedelic-assisted (PAT) model, where enhances alliance emotional openness while interventions provide structure lasting

Language: Английский

---

The Emergence of Psilocybin in Psychiatry and Neuroscience

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(4), P. 555 - 555

Published: April 9, 2025

Psilocybin, a naturally occurring psychedelic compound, has garnered renewed scientific interest for its potential in treating psychiatric and neurological disorders. This review systematically examines the latest research on psilocybin’s pharmacokinetics, pharmacodynamics, clinical efficacy, safety profile. Emerging evidence supports efficacy conditions such as major depressive disorder (MDD), treatment-resistant depression (TRD), anxiety, alcohol use disorders (AUD), cancer-related distress. Despite promising outcomes, significant barriers remain, including methodological constraints, regulatory hurdles, limited population diversity trials. Advances biosynthetic production optimized psychotherapeutic integration are necessary to ensure scalability accessibility. Future should focus long-term safety, dosing precision, neurobiological mechanisms refine therapeutic applications. provides critical foundation advancing evidence-based of psilocybin.

Language: Английский

---